Literature DB >> 22271656

Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.

David Goldberg1, Benjamin French, Peter Abt, Sandy Feng, Andrew M Cameron.   

Abstract

Candidates with hepatocellular carcinoma (HCC) within the Milan criteria (MC) receive standardized Model for End-Stage LIver Disease (MELD) exception points because of the projected risk of tumor expansion beyond the MC. Exception points at listing are meant to be equivalent to a 15% rusj if 90-day mortality, with additional points granted every 3 months, equivalent to a 10% increased morality risk. We analyzed the United Network for Organ Sharing database (January 1, 2005 to May 31, 2009) to compare the 90-day waitlist outcomes of HCC candidates and non-HCC candidates with similar MELD scores. Two hundred fifty-nine HCC candidates (4.1%) who were initially listed with 22 MELD exception points were removed because of death or clinical deterioration within 90 days of listing, whereas 283 non-HCC candidates (11.0%) with initial laboratory MELD scores of 21 to 23 were removed. Ninety-three HCC candidates (4.6%) with 25 exception points (after 3-6 months of waiting) were removed because of death or clinical deterioration within 90 days, whereas 805 non-HCC candidates (17.3%) with laboratory MELD scores of 24 to 26 were removed. Twenty HCC candidates (3.0%) with 28 exception points (after 6-9 months of waiting) were removed for death or clinical deterioration within 90 days, whereas 646 non-HCC candidates (23.6%) with laboratory MELD scores of 27 to 29 were removed. In multivariate logistic regression models, HCC candidates had significantly lower 90-day odds of waitlist removal for death or clinical deterioration (P < 0.001). Over time, the risk of waitlist removal for death or clinical deterioration was unchanged for HCC candidates (P = 0.17), whereas it increased significantly for non-HCC candidates. The current allotment of HCC exception points should be re-evaluated because of the stable risk of waitlist dropout for these candidates.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22271656      PMCID: PMC3319293          DOI: 10.1002/lt.23394

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  17 in total

1.  Organ Procurement and Transplantation Network--HRSA. Final rule with comment period.

Authors: 
Journal:  Fed Regist       Date:  1998-04-02

2.  Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements.

Authors:  Kiran Bambha; W Ray Kim; Walter K Kremers; Terry M Therneau; Patrick S Kamath; Russell Wiesner; Charles B Rosen; Jeff Thostenson; Joanne T Benson; E Rolland Dickson
Journal:  Am J Transplant       Date:  2004-11       Impact factor: 8.086

3.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.

Authors:  M Malinchoc; P S Kamath; F D Gordon; C J Peine; J Rank; P C ter Borg
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

4.  Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.

Authors:  Gerd Otto; Sascha Herber; Michael Heise; Ansgar W Lohse; Christian Mönch; Fernando Bittinger; Maria Hoppe-Lotichius; Marcus Schuchmann; Anja Victor; Michael Pitton
Journal:  Liver Transpl       Date:  2006-08       Impact factor: 5.799

Review 5.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

Review 6.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

7.  Model for end-stage liver disease: did the new liver allocation policy affect waiting list mortality?

Authors:  Mary T Austin; Benjamin K Poulose; Wayne A Ray; Patrick G Arbogast; Irene D Feurer; C Wright Pinson
Journal:  Arch Surg       Date:  2007-11

8.  Analysis of longitudinal data to evaluate a policy change.

Authors:  Benjamin French; Patrick J Heagerty
Journal:  Stat Med       Date:  2008-10-30       Impact factor: 2.373

9.  Model for end-stage liver disease (MELD) and allocation of donor livers.

Authors:  Russell Wiesner; Erick Edwards; Richard Freeman; Ann Harper; Ray Kim; Patrick Kamath; Walter Kremers; John Lake; Todd Howard; Robert M Merion; Robert A Wolfe; Ruud Krom
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

10.  Disparities in liver transplantation before and after introduction of the MELD score.

Authors:  Cynthia A Moylan; Carla W Brady; Jeffrey L Johnson; Alastair D Smith; Janet E Tuttle-Newhall; Andrew J Muir
Journal:  JAMA       Date:  2008-11-26       Impact factor: 56.272

View more
  41 in total

1.  Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.

Authors:  Sarah K Alver; Douglas J Lorenz; Kenneth Washburn; Michael R Marvin; Guy N Brock
Journal:  Transpl Int       Date:  2017-08-23       Impact factor: 3.782

2.  Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation.

Authors:  Alina M Allen; Julie K Heimbach; Joseph J Larson; Kristin C Mara; W Ray Kim; Patrick S Kamath; Terry M Therneau
Journal:  Transplantation       Date:  2018-10       Impact factor: 4.939

3.  Declining predictive performance of the MELD: Cause for concern or reflection of changes in clinical practice?

Authors:  Nadim Mahmud; David S Goldberg
Journal:  Am J Transplant       Date:  2019-10-23       Impact factor: 8.086

4.  Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Sebastiano Fabiano; Stefano Merolla; Valentina Funel; Francesca Di Giuliano; Matteo Manuelli; Giuseppe Tisone; Simona Francioso; Mario Angelico; Giampiero Palmieri; Giovanni Simonetti
Journal:  Radiol Med       Date:  2016-04-21       Impact factor: 3.469

Review 5.  The promise of organ and tissue preservation to transform medicine.

Authors:  Sebastian Giwa; Jedediah K Lewis; Luis Alvarez; Robert Langer; Alvin E Roth; George M Church; James F Markmann; David H Sachs; Anil Chandraker; Jason A Wertheim; Martine Rothblatt; Edward S Boyden; Elling Eidbo; W P Andrew Lee; Bohdan Pomahac; Gerald Brandacher; David M Weinstock; Gloria Elliott; David Nelson; Jason P Acker; Korkut Uygun; Boris Schmalz; Brad P Weegman; Alessandro Tocchio; Greg M Fahy; Kenneth B Storey; Boris Rubinsky; John Bischof; Janet A W Elliott; Teresa K Woodruff; G John Morris; Utkan Demirci; Kelvin G M Brockbank; Erik J Woods; Robert N Ben; John G Baust; Dayong Gao; Barry Fuller; Yoed Rabin; David C Kravitz; Michael J Taylor; Mehmet Toner
Journal:  Nat Biotechnol       Date:  2017-06-07       Impact factor: 54.908

6.  Who should undergo liver transplantation for hepatocellular carcinoma? Ablate, wait … and see!

Authors:  Willscott E Naugler; Barry Schlansky; Susan L Orloff
Journal:  Hepat Oncol       Date:  2014-03-20

7.  HCC patients suffer less from geographic differences in organ availability.

Authors:  C Schuetz; N Dong; E Smoot; N Elias; D A Schoenfeld; J F Markmann; H Yeh
Journal:  Am J Transplant       Date:  2013-09-06       Impact factor: 8.086

8.  Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database.

Authors:  David S Goldberg; Karen Krok; Sachin Batra; James F Trotter; Steven M Kawut; Michael B Fallon
Journal:  Gastroenterology       Date:  2014-01-08       Impact factor: 22.682

9.  Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Authors:  Neil Mehta; Jennifer L Dodge; Aparna Goel; John Paul Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Liver Transpl       Date:  2013-12       Impact factor: 5.799

Review 10.  Advances in liver transplantation allocation systems.

Authors:  Michael L Schilsky; Maryam Moini
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.